RT Journal Article
SR Electronic
T1 Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20182220
DO 10.1101/2020.09.01.20182220
A1 Vogl, Thomas
A1 Klompus, Shelley
A1 Leviatan, Sigal
A1 Kalka, Iris N.
A1 Godneva, Anastasia
A1 Shinar, Eilat
A1 Weinberger, Adina
A1 Segal, Eran
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.01.20182220.abstract
AB While cross-reactive T cells epitopes of SARS-CoV-2 and seasonal/common cold human coronaviruses (hCoVs) have been reported in individuals unexposed to SARS-CoV-2, potential antibody-based cross-reactivity is incompletely understood.Here, we have probed for high resolution antibody binding against all hCoVs represented as 1,539 peptides with a phage-displayed antigen library. We detected broad serum antibody responses against peptides of seasonal hCoVs in up to 75% of individuals. Recovered COVID-19 patients exhibited distinct antibody repertoires targeting variable SARS-CoV-2 epitopes, and could be accurately classified from unexposed individuals (AUC=0.96). Up to 50% of recovered patients also mounted antibody responses against unique epitopes of seasonal hCoV-OC43, that were not detectable in unexposed individuals.These results indicate substantial interindividual variability and antibody cross-reactivity between hCoVs from the direction of SARS-CoV-2 infections towards seasonal hCoVs. Our accurate high throughput assay allows profiling preexisting antibody responses against seasonal hCoVs cost-effectively and could inform on their protective nature against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.S.s COVID-19 research is supported by the Seerave Foundation. T.V. is supported by an Erwin Schroedinger fellowship (J 4256) from the Austrian Science Fund (FWF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research with the COVID-19 serum samples has been approved by the Weizmann Institute of Science s institutional review board (#1030-4), and by the Tel Aviv Sourasky Medical Center for the samples of unexposed individuals (#0658-12-TLV).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe majority of data generated or analyzed during this study are included in this published article (and its supplementary information files). Additional datasets generated and analysed during the current study are available from the corresponding author on reasonable request.